title: Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study.
abstract: To assess the prognosis of peripheral T-cell lymphoma unspecified, we retrospectively analyzed 385 cases fulfilling the criteria defined by the World Health Organization classification. Factors associated with a worse overall survival (OS) in a univariate analysis were age older than 60 years (P=.0002), equal to or more than 2 extranodal sites (P=.0002), lactic dehydrogenase (LDH) value at normal levels or above (P<.0001), performance status (PS) equal to or more than 2 (P< or =.0001), stage III or higher (P=.0001), and bone marrow involvement (P=.0001). Multivariate analysis showed that age (relative risk, 1.732; 95% CI, 1.300-2.309; P<.0001), PS (relative risk, 1.719; 95% CI, 1.269-2.327, P<.0001), LDH level (relative risk, 1.905; 95% CI, 1.415-2.564; P<.0001), and bone marrow involvement (relative risk, 1.454; 95% CI, 1.045-2.023; P=.026) were factors independently predictive for survival. Using these 4 variables we constructed a new prognostic model that singled out 4 groups at different risk: group 1, no adverse factors, with 5-year and 10-year OS of 62.3% and 54.9%, respectively; group 2, one factor, with a 5-year and 10-year OS of 52.9% and 38.8%, respectively; group 3, 2 factors, with 5-year and 10-year OS of 32.9% and 18.0%, respectively; group 4, 3 or 4 factors, with a 5-year and 10-year OS of 18.3 and 12.6%, respectively (P< or =.0001; log-rank, 66.79).
authors.affiliation: Struttura Complessa Ematologia Azienda Ospedaliera S Croce e Carle, Cuneo, Italy. gallamini.a@ospedale.cuneo.it
authors.forename: Andrea
authors.initials: A
authors.lastname: Gallamini
authors.forename: Caterina
authors.initials: C
authors.lastname: Stelitano
authors.forename: Roberta
authors.initials: R
authors.lastname: Calvi
authors.forename: Monica
authors.initials: M
authors.lastname: Bellei
authors.forename: Daniele
authors.initials: D
authors.lastname: Mattei
authors.forename: Umberto
authors.initials: U
authors.lastname: Vitolo
authors.forename: Fortunato
authors.initials: F
authors.lastname: Morabito
authors.forename: Maurizio
authors.initials: M
authors.lastname: Martelli
authors.forename: Ercole
authors.initials: E
authors.lastname: Brusamolino
authors.forename: Emilio
authors.initials: E
authors.lastname: Iannitto
authors.forename: Francesco
authors.initials: F
authors.lastname: Zaja
authors.forename: Sergio
authors.initials: S
authors.lastname: Cortelazzo
authors.forename: Luigi
authors.initials: L
authors.lastname: Rigacci
authors.forename: Liliana
authors.initials: L
authors.lastname: Devizzi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Todeschini
authors.forename: Gino
authors.initials: G
authors.lastname: Santini
authors.forename: Maura
authors.initials: M
authors.lastname: Brugiatelli
authors.forename: Massimo
authors.initials: M
authors.lastname: Federico
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018579:Patient Selection; D011379:Prognosis; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents